Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010166382> ?p ?o ?g. }
- W3010166382 endingPage "460" @default.
- W3010166382 startingPage "453" @default.
- W3010166382 abstract "Background The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. Methods The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. Findings Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI −8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [−31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. Interpretation The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. Funding Boehringer Ingelheim." @default.
- W3010166382 created "2020-03-13" @default.
- W3010166382 creator A5000252461 @default.
- W3010166382 creator A5000308788 @default.
- W3010166382 creator A5000381347 @default.
- W3010166382 creator A5000598745 @default.
- W3010166382 creator A5001408794 @default.
- W3010166382 creator A5001763121 @default.
- W3010166382 creator A5001926822 @default.
- W3010166382 creator A5002422862 @default.
- W3010166382 creator A5002731286 @default.
- W3010166382 creator A5003167593 @default.
- W3010166382 creator A5004112494 @default.
- W3010166382 creator A5004445358 @default.
- W3010166382 creator A5005533579 @default.
- W3010166382 creator A5006321426 @default.
- W3010166382 creator A5006969715 @default.
- W3010166382 creator A5006993828 @default.
- W3010166382 creator A5007461514 @default.
- W3010166382 creator A5007704589 @default.
- W3010166382 creator A5007804440 @default.
- W3010166382 creator A5007887191 @default.
- W3010166382 creator A5009003396 @default.
- W3010166382 creator A5009091055 @default.
- W3010166382 creator A5009383674 @default.
- W3010166382 creator A5009572751 @default.
- W3010166382 creator A5009823357 @default.
- W3010166382 creator A5010099708 @default.
- W3010166382 creator A5010115182 @default.
- W3010166382 creator A5011024503 @default.
- W3010166382 creator A5012005309 @default.
- W3010166382 creator A5012539336 @default.
- W3010166382 creator A5013041282 @default.
- W3010166382 creator A5014703126 @default.
- W3010166382 creator A5015537103 @default.
- W3010166382 creator A5019226936 @default.
- W3010166382 creator A5019390272 @default.
- W3010166382 creator A5019434255 @default.
- W3010166382 creator A5019441565 @default.
- W3010166382 creator A5019763846 @default.
- W3010166382 creator A5020464853 @default.
- W3010166382 creator A5020811444 @default.
- W3010166382 creator A5020859312 @default.
- W3010166382 creator A5021098628 @default.
- W3010166382 creator A5021533720 @default.
- W3010166382 creator A5021643144 @default.
- W3010166382 creator A5021695259 @default.
- W3010166382 creator A5022962530 @default.
- W3010166382 creator A5023093481 @default.
- W3010166382 creator A5024201886 @default.
- W3010166382 creator A5024611768 @default.
- W3010166382 creator A5025137523 @default.
- W3010166382 creator A5025171057 @default.
- W3010166382 creator A5025872899 @default.
- W3010166382 creator A5026135954 @default.
- W3010166382 creator A5026433459 @default.
- W3010166382 creator A5026986582 @default.
- W3010166382 creator A5027118818 @default.
- W3010166382 creator A5027241081 @default.
- W3010166382 creator A5027989298 @default.
- W3010166382 creator A5028337025 @default.
- W3010166382 creator A5029238128 @default.
- W3010166382 creator A5030294739 @default.
- W3010166382 creator A5030566289 @default.
- W3010166382 creator A5032253395 @default.
- W3010166382 creator A5033246044 @default.
- W3010166382 creator A5033528740 @default.
- W3010166382 creator A5033586503 @default.
- W3010166382 creator A5034173750 @default.
- W3010166382 creator A5034180464 @default.
- W3010166382 creator A5034439885 @default.
- W3010166382 creator A5034801254 @default.
- W3010166382 creator A5035168811 @default.
- W3010166382 creator A5036577393 @default.
- W3010166382 creator A5037402194 @default.
- W3010166382 creator A5038615410 @default.
- W3010166382 creator A5039064134 @default.
- W3010166382 creator A5042491943 @default.
- W3010166382 creator A5043782633 @default.
- W3010166382 creator A5045393300 @default.
- W3010166382 creator A5045765914 @default.
- W3010166382 creator A5046098333 @default.
- W3010166382 creator A5046760281 @default.
- W3010166382 creator A5046824987 @default.
- W3010166382 creator A5047628060 @default.
- W3010166382 creator A5049221790 @default.
- W3010166382 creator A5049341588 @default.
- W3010166382 creator A5050641750 @default.
- W3010166382 creator A5051029267 @default.
- W3010166382 creator A5051229279 @default.
- W3010166382 creator A5052160402 @default.
- W3010166382 creator A5052219607 @default.
- W3010166382 creator A5052471232 @default.
- W3010166382 creator A5053225741 @default.
- W3010166382 creator A5053926844 @default.
- W3010166382 creator A5054118362 @default.
- W3010166382 creator A5055570107 @default.
- W3010166382 creator A5055683618 @default.